Hemofarm invests 200 millions euro in its Serbian division
The German ambassador to Serbia reported good business cooperation after he visited the branch of the German company Hemofarm pharmaceuticals in Sabac, Serbia at the end of July this year.
Axel Dittmann, who works as the German ambassador to Serbia, has noted the smooth work of the Hemofarm plant in Sabac and asserted that the city authorities and the company have been working together very effectively.
Hemofarm pharmaceuticals is one of the biggest investment projects in Serbia, providing over 2,500 people employment positions of various kinds. This helps both the regions of Vrsac in northern Serbia and Sabac in western Serbia grow and develop economically.
The role of the relation between the city authorities and the company in the economic growth of Sabac is that it potentially attracts more foreign investors and thus it enables the region to become the main source of future growth in the area.
The visit of Axel Dittmann to the Sabac plant of Hemofarm has been the symbolic celebration of Hemofarm’s entrance into the STADA group ten years ago. STADA is a publicly traded, international company working on the health-care market.
It is based in Germany and has invested over 200 million euro in Hemofarm since it has acquired the company. The money invested has been used for upgrading the work equipment, increasing the quality and quantity of production and also the efficiency and qualification of workers.
The first Hemofarm division in Serbia was founded in the middle of the 1960’s in Vrsac. The plant in Sabac, which is a subsidiary, has become a part of Hemofarm through a merge that took place last year. Today the company has subsidiaries in Macedonia, Montenegro, Romania, Bosnia and Herzegovina and representative offices in Algeria and Serbia.
Hemofarm produces over 4 billion medicines per year and it trades on 3 continents. It has a significant place in the world market of pharmaceuticals serving 38 markets. It complies with high standards for producing pharmaceuticals and the norms of Business Social Compliance Initiative (BSCI).
LATEST issue 1/2019